Multiple Myeloma Research Consortium Opens Six New Clinical Trials in 2014
Oct 1 14
Multiple Myeloma Research Consortium announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year. Phase I, Multicenter, Open-Label, Dose-Escalation Combination study of Marizomib, Pomalidomide, and Low-Dose Dexamethasone (PMD) in subjects with relapsed or refractory multiple myeloma. Marizomib is a novel proteasome inhibitor from Triphase -- in the same class as Velcade (bortezomib) and Kyprolis (carfilzomib) -- that has been studied in Phase I single agent trial in the MMRC. Investigators believe that it can work in patients who are resistant to other proteasome inhibitors. Multicenter, Phase I/IIb Study of Ibrutinib, in combination with Kyprolis in subjects with relapsed or relapsed and refractory multiple myeloma. Ibrutinib blocks a protein called Bruton's tyrosine kinase (Btk), and is an oral drug already approved by FDA for Chronic Lymphocytic Leukemia. Phase I Study of the combination of a Selective Inhibitor of Nuclear export (SINE), Selinexor (KPT-330), with Kyprolis and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Phase I Study of SAR650984 for the treatment of relapsed or refractory multiple myeloma (NCT1084252). SAR650984 is an anti-CD 38 monoclonal antibody therapy that is being studied in combination with lenalidomide and dexamethasone in the MMRC. Early results suggest that this combination treatment may be effective in patients who have failed other options. A Phase I/II trial of Ixazomib (MLN9708) in combination with Pomalyst (pomalidomide) and dexamethasone for relapsed or relapsed refractory multiple myeloma. MLN9708 is the first oral proteasome inhibitor and provides a much easier and more convenient route of drug administration. Phase I, Open Label, Dose-Escalation study of first in man study of CB-5083, the first p97 inhibitor to enter clinical trials. Several MMRC member institutions worked closely with manufacturer Cleave Biosciences on the preclinical work, which suggested activity in multiple myeloma. CB-5083 targets a novel protein that is involved in protein degradation and the proteasome pathway and inhibits this pathway at a different intervention point than the proteasome inhibitors, Velcade and Kyprolis.